Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.

"Financial & competing interests disclosure: All authors have read and approved the submission. A Horga, K Pietropaolo, K Perkins and B Belanger are employees of Atea. DR Kuritzkes has received consulting honoraria from Atea, Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Moderna, Novartis, Pfizer and Shionogi; research support from Atea, Gilead and Novartis; speaking honoraria from Gilead, Janssen and Novartis; and fees for expert testimony on behalf of Gilead. JJ Kowalczyk has nothing to disclose. K Lin is a former employee of Atea. J Hammond is an employee and stakeholder of Atea. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.: Medical writing support was provided by R Myers of PRECISIONscientia of PA, USA and funded by the study sponsor, Atea Pharmaceuticals, Inc. (MA, USA)."

"Atea Pharmaceuticals"

"Clinical Trial Registration: NCT04396106 (ClinicalTrials.gov)"